Overview Dividends

(OFIX) Orthofix Medical - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US68752M1080

Bone Stimulators, Spine Implants, Biological Grafts, Navigation Systems, Limb Fixation

OFIX EPS (Earnings per Share)

EPS Growth (3Y CAGR): -4.64%
EPS Trend (3Y Correlation): -44.9%

OFIX Revenue

Revenue Growth (3Y CAGR): 23.37%
Revenue Trend (3Y Correlation): 77.6%

Description: OFIX Orthofix Medical October 24, 2025

Orthofix Medical Inc. (NASDAQ:OFIX) is a medical-technology firm that sells bone-growth stimulation devices, spine fixation and motion-preservation implants, biological bone matrices, and navigation-software tools across the United States, Europe, Brazil and other markets. The business is split into two operating segments: Global Spine, which focuses on spinal fusion adjuncts, non-invasive fracture therapies, and 7D flash navigation systems; and Global Orthopedics, which provides external and internal fixation products for limb reconstruction and deformity correction.

Both segments are sold through a mix of direct sales representatives and third-party distributors to hospitals, health-systems and physicians. The company, originally Orthofix International N.V., rebranded to Orthofix Medical Inc. in 2018 and is headquartered in Lewisville, Texas.

Key recent metrics (FY 2023): revenue of approximately $315 million, a 7 % year-over-year increase driven largely by higher spine-device sales; operating margin of 5.2 %; and a cash-burn rate of $28 million, offset by a $45 million revolving credit facility. The spine-device market is projected to grow at a 6-8 % CAGR through 2028, buoyed by an aging population and expanding minimally invasive surgery adoption, while reimbursement pressures and supply-chain volatility remain material risk factors.

For a deeper quantitative assessment, you may find ValueRay’s platform useful for drilling into OFIX’s financials and peer comparisons.

OFIX Stock Overview

Market Cap in USD	610m
Sub-Industry	Health Care Equipment
IPO / Inception	1992-04-24

OFIX Stock Ratings

Growth Rating	-51.7%
Fundamental	37.5%
Dividend Rating	-
Return 12m vs S&P 500	-28.0%
Analyst Rating	4.0 of 5

OFIX Dividends

Currently no dividends paid

OFIX Growth Ratios

Growth Correlation 3m	54.5%
Growth Correlation 12m	-63.9%
Growth Correlation 5y	-85.6%
CAGR 5y	-5.56%
CAGR/Max DD 3y (Calmar Ratio)	-0.10
CAGR/Mean DD 3y (Pain Ratio)	-0.18
Sharpe Ratio 12m	-0.81
Alpha	-32.70
Beta	0.888
Volatility	47.69%
Current Volume	225.4k
Average Volume 20d	240.3k
Stop Loss	14 (-4.6%)
Signal	-0.96

Piotroski VR‑10 (Strict, 0-10) 4.0

Net Income (-123.7m TTM) > 0 and > 6% of Revenue (6% = 48.5m TTM)

FCFTA 0.00 (>2.0%) and ΔFCFTA 8.27pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 30.59% (prev 29.82%; Δ 0.77pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.03 (>3.0%) and CFO 28.6m > Net Income -123.7m (YES >=105%, WARN >=100%)

Net Debt (139.1m) to EBITDA (3.68m) ratio: 37.78 <= 3.0 (WARN <= 3.5)

Current Ratio 2.67 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (39.5m) change vs 12m ago 3.90% (target <= -2.0% for YES)

Gross Margin 68.43% (prev 65.52%; Δ 2.91pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 94.12% (prev 87.49%; Δ 6.63pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -3.29 (EBITDA TTM 3.68m / Interest Expense TTM 28.6m) >= 6 (WARN >= 3)

Altman Z'' -1.07

(A) 0.30 = (Total Current Assets 395.8m - Total Current Liabilities 148.4m) / Total Assets 837.2m

(B) -0.41 = Retained Earnings (Balance) -343.3m / Total Assets 837.2m

(D) -0.89 = Book Value of Equity -338.5m / Total Liabilities 378.8m

Total Rating: -1.07 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 37.52

1. Piotroski 4.0pt = -1.0

2. FCF Yield 0.06% = 0.03

3. FCF Margin 0.06% = 0.01

4. Debt/Equity 0.45 = 2.40

5. Debt/Ebitda 37.78 = -2.50

6. ROIC - WACC (= -22.14)% = -12.50

7. RoE -25.43% = -2.50

8. Rev. Trend 77.59% = 5.82

9. EPS Trend -44.92% = -2.25

What is the price of OFIX shares?

As of November 08, 2025, the stock is trading at USD 14.68 with a total of 225,367 shares traded.
Over the past week, the price has changed by -3.11%, over one month by +5.35%, over three months by +17.80% and over the past year by -17.89%.

Is Orthofix Medical a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Orthofix Medical (NASDAQ:OFIX) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 37.52 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of OFIX is around 13.53 USD . This means that OFIX is currently overvalued and has a potential downside of -7.83%.

Is OFIX a buy, sell or hold?

Orthofix Medical has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy OFIX.

Strong Buy: 2
Buy: 1
Hold: 2
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the OFIX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	22.6	53.6%
Analysts Target Price	22.6	53.6%
ValueRay Target Price	15	1.8%

OFIX Fundamental Data Overview November 03, 2025

Market Cap USD = 609.8m (609.8m USD * 1.0 USD.USD)
P/E Forward = 31.5457
P/S = 0.7537
P/B = 1.2244
P/EG = 3.1578
Beta = 0.888
Revenue TTM = 809.0m USD
EBIT TTM = -94.1m USD
EBITDA TTM = 3.68m USD
Long Term Debt = 157.0m USD (from longTermDebt, last quarter)
Short Term Debt = 3.85m USD (from shortTermDebt, last quarter)
Debt = 204.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 139.1m USD (from netDebt column, last quarter)
Enterprise Value = 748.9m USD (609.8m + Debt 204.7m - CCE 65.6m)
Interest Coverage Ratio = -3.29 (Ebit TTM -94.1m / Interest Expense TTM 28.6m)
FCF Yield = 0.06% (FCF TTM 461.0k / Enterprise Value 748.9m)
FCF Margin = 0.06% (FCF TTM 461.0k / Revenue TTM 809.0m)
Net Margin = -15.29% (Net Income TTM -123.7m / Revenue TTM 809.0m)
Gross Margin = 68.43% ((Revenue TTM 809.0m - Cost of Revenue TTM 255.4m) / Revenue TTM)
Gross Margin QoQ = 68.69% (prev 62.80%)
Tobins Q-Ratio = 0.89 (Enterprise Value 748.9m / Total Assets 837.2m)
Interest Expense / Debt = 1.93% (Interest Expense 3.95m / Debt 204.7m)
Taxrate = 1.00% (-142.0k / -14.2m)
NOPAT = -93.2m (EBIT -94.1m * (1 - 1.00%)) [loss with tax shield]
Current Ratio = 2.67 (Total Current Assets 395.8m / Total Current Liabilities 148.4m)
Debt / Equity = 0.45 (Debt 204.7m / totalStockholderEquity, last quarter 458.3m)
Debt / EBITDA = 37.78 (Net Debt 139.1m / EBITDA 3.68m)
Debt / FCF = 301.8 (Net Debt 139.1m / FCF TTM 461.0k)
Total Stockholder Equity = 486.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.78% (Net Income -123.7m / Total Assets 837.2m)
RoE = -25.43% (Net Income TTM -123.7m / Total Stockholder Equity 486.4m)
RoCE = -14.63% (EBIT -94.1m / Capital Employed (Equity 486.4m + L.T.Debt 157.0m))
RoIC = -14.70% (negative operating profit) (NOPAT -93.2m / Invested Capital 633.8m)
WACC = 7.43% (E(609.8m)/V(814.5m) * Re(9.29%) + D(204.7m)/V(814.5m) * Rd(1.93%) * (1-Tc(0.01)))
Discount Rate = 9.29% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.91%
[DCF Debug] Terminal Value 75.87% ; FCFE base≈461.0k ; Y1≈523.4k ; Y5≈715.6k
Fair Price DCF = 0.25 (DCF Value 9.91m / Shares Outstanding 39.5m; 5y FCF grow 15.76% → 3.0% )
EPS Correlation: -44.92 | EPS CAGR: -4.64% | SUE: 0.70 | # QB: 0
Revenue Correlation: 77.59 | Revenue CAGR: 23.37% | SUE: 3.28 | # QB: 3

Additional Sources for OFIX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle